Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity
| Authors | |
|---|---|
| Year of publication | 2007 |
| Type | Article in Proceedings |
| Conference | Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop |
| MU Faculty or unit | |
| Citation | |
| Field | Psychiatry, sexuology |
| Keywords | bulimia; CYP2D6; paroxetine |
| Description | P450 enzymes are oxidase systems. These enzymes oxidize endogenous and exogenous compounds and usually render them less active, preparing them for elimination from the body. More than 40 individual P450 enzymes have been identified. 2D6 play important role in drug metabolism. SSRI (serotonin reuptake inhibitors) therapy is used in bulimia. There are SSRI, especially paroxetine, with a SSRI-inhibiting effect. This fact may lead to a change of phenotype. Phenotyping enables to identify the current activity of the enzyme. The study included patients diagnosed with bulimia. The goal of the study was to evaluate the efficacy of paroxetine treatment in female patients with mental bulimia (MB) while monitoring CYP2D6 activity. Treatment was evaluated on EAT, HAMA, CGI and UKU scales. CYP2D6 activity phenotyping was performed using the dextromethorphan test. The expectation of a significant improvement in poor metabolizers and consequently slower paroxetine degradation was confirmed on the scale for eating behaviour. |
| Related projects: |